Sue Leurgans to Hallucinations
This is a "connection" page, showing publications Sue Leurgans has written about Hallucinations.
Connection Strength
1.744
-
Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord. 2008 Aug 15; 23(11):1541-5.
Score: 0.316
-
Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
Score: 0.271
-
Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
Score: 0.265
-
Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
Score: 0.247
-
Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord. 1999 Jan; 14(1):117-21.
Score: 0.162
-
Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
Score: 0.095
-
Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry. 2008 Jun; 23(6):598-603.
Score: 0.078
-
The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol. 2006 May; 63(5):713-6.
Score: 0.067
-
Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004 Aug; 61(8):1280-4.
Score: 0.060
-
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
Score: 0.050
-
Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001 Feb; 58(2):209-13.
Score: 0.047
-
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology. 2000 Sep 26; 55(6):789-94.
Score: 0.046
-
Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):289-95.
Score: 0.040